Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 4/20 | 0.48 |
| ▸ | CTSL | P07711 | 3/20 | 0.48 |
| ▸ | CTSK | P43235 | 5/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29437121 | 0.86 | SMN1; SMN2 (0.62) | SMN1; SMN2MMEECE1CTSSCTSL | |
| SCHEMBL36611 | 0.85 | SMN1; SMN2 (0.61) | SMN1; SMN2MMEECE1CTSSCTSL | |
| SCHEMBL8496964 | 0.85 | SMN1; SMN2 (0.61) | SMN1; SMN2MMEECE1CTSSCTSL | |
| Hydroxyamine SCHEMBL9197242 | 0.84 | SMN1; SMN2 (0.60) | SMN1; SMN2MMEECE1CTSSCTSL | |
| SCHEMBL19706959 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2MMEECE1CTSSCTSL | |
| SCHEMBL9228658 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2MMEECE1CTSSCTSL | |
| SCHEMBL9228661 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2MMEECE1CTSSCTSL | |
| SCHEMBL10385459 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2MMEECE1CTSSCTSL | |
| SCHEMBL30914622 | 0.82 | SMN1; SMN2 (0.58) | SMN1; SMN2MMEECE1CTSSCTSL | |
| SCHEMBL10385461 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2MMEECE1CTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12214050-B2 | C-terminal lysine conjugated immunoglobulins | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-02-04 | — | — | US | disclosed |
| US-11753669-B2 | Lysine conjugated immunoglobulins | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-09-12 | — | — | US | disclosed |
| CN-109475642-B | Lysine conjugated immunoglobulins | 卫材R&D管理有限公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-4032902-A1 | C-TERMINAL LYSINE CONJUGATED IMMUNOGLOBULINS | Eisai R&D Management Co., Ltd. (JP) | 2022-07-27 | — | — | EP | disclosed |
| US-20220088212-A1 | C-TERMINAL LYSINE CONJUGATED IMMUNOGLOBULINS | EISAI CO., LTD. (JP) | 2022-03-24 | — | — | US | disclosed |
| EP-3390440-B1 | C-TERMINAL LYSINE CONJUGATED IMMUNOGLOBULINS | EISAI R&D MAN CO LTD (JP) | 2022-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12214050-B2 | C-terminal lysine conjugated immunoglobulins | TGM3, TGM1, TGM2 | SMN1; SMN2 4749/4885MME 2439/4885ECE1 2046/4885 |
| US-11753669-B2 | Lysine conjugated immunoglobulins | IGSF11, TGM1, IGLV6-57 | SMN1; SMN2 4618/4885MME 2523/4885ECE1 2584/4885 |
| US-20220088212-A1 | C-TERMINAL LYSINE CONJUGATED IMMUNOGLOBULINS | TGM3, TGM1, TGM2 | SMN1; SMN2 4749/4885MME 2439/4885ECE1 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.